Gene expression profiling identifies clinically relevant subtypes of prostate cancer.

By J. Lapointe, Chunde Li, J. Higgins, M. van de Rijn, Eric Bair, K. Montgomery, M. Ferrari, L. Egevad, W. Rayford, U. Bergerheim and 7 more. Proceedings of the National Academy of Sciences of the United States of America, 2004

1,369 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/5075cd2006b94c25766accc5594a9ecd55049382

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Integrative genomic profiling of human prostate cancer (2010, background): “, 2002), these analyses have not identified robust subtypes of prostate cancer with different prognoses (Febbo and Sellers, 2003; Lapointe et al., 2004; Singh et al., 2002).”
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. (2005, methodology): “…gene expression microarrays to profile prostate cancer tissues (Dhanasekaran CANCER CELL : NOVEMBER 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIE et al., 2001; Lapointe et al., 2004; LaTulippe et al., 2002; Luo et al., 2001, 2002b; Magee et al., 2001; Singh et al., 2002; Welsh et al., 2001; Yu et al.,…”
Clustering cancer gene expression data: a comparative study (2008, neutral): “Armstrong-V1 [52] Affy Blood 72 2 24,48 12582 1081 Armstrong-V2 [52] Affy Blood 72 3 24,20,28 12582 2194 Bhattacharjee [9] Affy Lung 203 5 139,17,6,21,20 12600 1543 Chowdary [13] Affy Breast, Colon 104 2 62,42 22283 182 Dyrskjot [14] Affy Bladder 40 3 9,20,11 7129 1203 Golub-V1 [3] Affy Bone marrow ”
Mucins in cancer: function, prognosis and therapy (2009, background): “Gene expression profiling of human prostate cancers has also shown that MUC1 is upregulated in subgroups with an increased risk of recurrenc”
The Estrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer (2014, neutral): “(12,143) 73 Prostate samples (PE-RNA-SEQ) 0 0.”
Revisiting Global Gene Expression Analysis (2012, neutral): “…methods (Alizadeh et al., 2000; Beer et al., 2002; Berger et al., 2010; Bhattacharjee et al., 2001; Bittner et al., 2000; Golub et al., 1999; Lapointe et al., 2004; Northcott et al., 2012; Ramaswamy et al., 2001; Ross et al., 2000; Schmitz et al., 2012; Shipp et al., 2002; Su et al.,…”
Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines (2014, neutral): “[38-43].”
Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. (2008, background): “It is notable that a similar frequency of REDD1 down-regulation was observed in an expression profiling study of 41 patient-matched normal prostate tissues versus invasive prostate carcinomas (Lapointe et al. 2004).”
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. (2006, background): “However, tumor cells can induce increased expression of COL1A2 in their associated stromal cells, and this induced COL1A2 expression has been identified as part of a molecular signature of metastatic tumors that could be identified in the corresponding primary tumors, including prostate cancer (21, ”